Effectiveness of Shared Decision Making(SDM)on Patients With Poor Control Type 2 Diabetes (SDM)

September 4, 2026 updated by: Fooyin University
The study is a pilot study, using a convenient sampling method, targeting at outpatient patients with type 2 diabetes who participate in the diabetes co-care program and poor blood sugar control as the research subjects, and randomly assigned. The number of samples is expected to receive 30 patients in each group. The attrition rate estimates about 20%, so there should be 76 people in total, and 38 people in each group. The experimental group was involved in SDM health education; the control group was involved in routine health education. After the implementation of the measures, the self-efficacy and health promotion behavior changes of the two groups and the effectiveness of disease control (glycated hemoglobin, body mass index, waist circumference) were tracked.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background Diabetes and hyperglycemia not only increase the risk of complications of cardiovascular disease and lead to a situation involving exposure to danger of death. Meanwhile, the patient's self-management is one of the key factors affecting the quality control of blood sugar. Thereby, Shared Decision Making (SDM) is a patient-centered medical implementation method that healthcare professionals and patients jointly participate in treatment decision-making to reach a consensus, which can stimulate the health care ability of participants to achieve treatment goals.

Purpose: This research aims to implement the SDM model based on self-efficacy theory through individualized decision-making to strengthen the behavioral motivation of diabetic patients and finally, to improve the patient's health promotion behavior and the effectiveness of blood sugar control.

Method: Study Type: Interventional Actual Enrollment:76 participants Allocation:Randomized Intervention Model:Parallel Assignment Masking:Single(Participant)

Expected results:

It is hoped that the implementation of SDM model will be used to strengthen the behavioral motivation of diabetic patients through individualized decision-making, and to confirm whether it can effectively improve the patient's health behavior and the effectiveness of disease control.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Taiwan
      • Tainan, Taiwan, Taiwan, 709204
        • An Nan Hospition-China Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged>20y/o
  • Diagnosed by a physician as type 2 diabetes
  • The Diabetes Participated in the Diabetes Shared Care Network
  • Glycosylated hemoglobin (A1C)> 7.5%
  • Can communicate in Chinese or Taiwanese.

Exclusion Criteria:

  • People with mental or cognitive impairment who cannot communicate
  • Health Literacy score lower than 6 points

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group:as usual care
The control group received as usual care.
Experimental: Experimental group:The intervention of SDM
The experimental group received the intervention of SDM 3 times for 3 months,
The experimental group received the intervention of SDM 3times/month for 3months, then follow the health promotion behavior compliance by phone once a month.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diabetes self-efficacy scale
Time Frame: Pre-test (baseline)
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
Pre-test (baseline)
Diabetes self-efficacy scale
Time Frame: 1 months after intervnetion
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
1 months after intervnetion
Diabetes self-efficacy scale
Time Frame: 3 months after intervnetion
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
3 months after intervnetion
Diabetes health literacy scale
Time Frame: Pre-test (baseline)
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
Pre-test (baseline)
Diabetes health literacy scale
Time Frame: 3 months after intervnetion
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
3 months after intervnetion
Diabetes health promotion scale
Time Frame: Pre-test (baseline)
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
Pre-test (baseline)
Diabetes health promotion scale
Time Frame: 1 months after intervnetion
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
1 months after intervnetion
Diabetes health promotion scale
Time Frame: 3 months after intervnetion
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
3 months after intervnetion
Hemoglobin A1C (HbA1c) Test
Time Frame: 3 months after intervnetion
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months.
3 months after intervnetion
Hemoglobin A1C (HbA1c) Test
Time Frame: Pre-test (baseline)
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months
Pre-test (baseline)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2020

Primary Completion (Actual)

October 30, 2020

Study Completion (Actual)

June 30, 2021

Study Registration Dates

First Submitted

March 14, 2022

First Submitted That Met QC Criteria

September 4, 2026

First Posted (Actual)

September 9, 2026

Study Record Updates

Last Update Posted (Actual)

September 9, 2026

Last Update Submitted That Met QC Criteria

September 4, 2026

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • FooyinU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.